| Chemical Properties | Back Directory | [density ]
1.49±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
lyophilized powder | [pka]
3.22±0.10(Predicted) | [color ]
white to beige | [InChIKey]
RJEAEIUDNCLZNN-HXDGCKLRNA-N |
| Hazard Information | Back Directory | [Description]
Peptide5 is a connexin43 mimetic peptide. Reduces swelling, astrogliosis, neuroinflammation and neuronal cell death following spinal cord injury ex vivo and in vivo. Exhibits analgesic effects in models of neuropathic pain. | [Uses]
Peptide5, a connexin 43 mimetic peptide, reduce animals swelling, astrogliosis, and neuronal cell death after spinal cord injury[1] | [in vitro]
Peptide5, significantly reduces the degree of spinal cord injury (SCI) in a rodent ex vivo model. Peptide5 produces the more significant reduction in swelling and is analyzed further. Treatment with peptide5 reduced both the level of Cx43 and the number of glial fibrillary acidic protein (GFAP)-positive astrocytes, and at the same time reduces the loss of NeuN- and SMI-32–positive neurons in a concentration- and time-dependent manner.
| [in vivo]
Peptide5 is could be used to treat traumatic spinal cord injured rats[1].
| [References]
[1] Simon J O'Carroll, et al. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. Cell Commun Adhes. 2008 May;15(1):27-42. DOI:10.1080/15419060802014164
[2] Yilin Mao, et al. Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. Exp Brain Res. 2017 Oct;235(10):3033-3048. DOI:10.1007/s00221-017-5023-3 |
|
| Company Name: |
Combio (Suzhou) Ltd.
|
| Telephone: |
17751201929; 17751201929 |
| Website: |
http://www.combiosz.com/ |
|